GLIOBID · Guiding glioblastoma treatments by decrypting tumor biomechanics via Magnetic Resonance Elastography.
„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“
- Период
- 2023-04-01 → 2026-03-31
- Финансиране от ЕС
- 284 180 €
- Участници
- 2
- Схема
- HORIZON-TMA-MSCA-PF-GF
Линиите свързват координатора с партньорите.
Накратко на български
Глиобластомата, най-агресивният мозъчен тумор, се изследва чрез измерване на физическите му свойства като твърдост и вискозитет. Това помага за по-ранно и точно проследяване на ефекта от лечението, тъй като стандартните скенерни изследвания не виждат тези промени.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Guiding glioblastoma treatments by decrypting tumor biomechanics via Magnetic Resonance Elastography.
Glioblastoma multiforme (GBM) is the most aggressive and deadly form of brain tumour. Despite surgery, radiotherapy and chemotherapy, most patients experience tumour recurrence within months, and overall survival remains dismally low. One of the key challenges in treating GBM is that standard imaging tools do not capture the full complexity of the tumour microenvironment — particularly the physical barriers that block drug delivery and promote tumour progression. GLIOBID addresses this problem by developing and applying advanced imaging techniques to non-invasively measure the biomechanical properties of brain tumours, such as tissue stiffness, viscosity, and pressure. These properties are deeply linked to the biological processes that drive tumour invasion, vascular collapse, and therapy resistance. By mapping how tumours change mechanically in response to treatment, GLIOBID aims to create a new way to monitor whether therapies are working — much earlier and more precisely than what current MRI scans allow. The project uses Magnetic Resonance Elastography (MRE), an imaging technique that uses Magnetic resonance Imaging to measure how tissue behave when vibrations are sent. The resulting data provide a “biomechanical fingerprint” of the tumour. The main objectives of GLIOBID are: 1. To measure how therapy affects tumour stiffness, viscosity, and vascular structure. 2. To use MRE to estimate tumour pressure non-invasively. 3. To translate these advanced MRE tools into the clinical setting. Ultimately, GLIOBID aims to support better treatment planning and monitoring in glioblastoma — a critical unmet medical need in Europe and worldwide.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
Glioblastoma multiforme (GBM) is the most common and deadly type of primary brain tumour, carrying a dire prognosis with a median survival of 14.6 months for patients undergoing standard treatments. The causes of poor clinical prognosis are late diagnosis, diffuse infiltration, pseudo necrosis, high neovascularization and resistance to therapy. In principle, drugs can reach the tumors via the vascular system, but the tumor microenvironment plays the role of an antagonist to any efficient drug delivery whereby reducing treatment efficacy. Recent treatments combine chemotherapy with drugs which aim at re-normalising the tumor microenvironment by releasing the mechanical pressure and/or by reducing the angiogenesis. However, there are yet no imaging biomarkers clinically available which can disentangle the different effects of the therapy on the components of the TME. This hinders patient management in particular dosage. GLIOBID project aim at disentangling the therapy impact on tissue integrity and pressure from the modulation of tumour vasculature by quantifying tissue rheology with magnetic resonance Elastography (MRE). This imaging breakthrough will allow to assess the effect of treatments on the main target – the tumor - and the pathways to reach it – the vessels and the tumour microenvironment - providing a unique guidance to tailor combined therapies based on component-specific biomarkers. GLIOBID will involve the main experts in the field of imaging and cancer biology, creating a highly multidisciplinary and eminently clinical environment. This together with the complementary expertise of researcher and hosting institutions will provide the best conditions for decrypting the complexity of the problem and find approaches translatable to the clinical routine. GLIOBID will potentially allow a paradigm shift from the current TREAT-THEN-OBSERVE approach to an OBSERVE-THUS-TREAT approach.
Оригинален текст от CORDIS (на английски).
Участници
- OSLO UNIVERSITETSSYKEHUS HF · OsloКоординаторНорвегия
- BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY · STANFORDСъединени щати
Връзки
Данни: CORDIS, © Европейски съюз